Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00GNI
|
|||
| Former ID |
DIB008516
|
|||
| Drug Name |
REGN-727
|
|||
| Synonyms |
Alirocumab; Alirocumab); RENG-727; Anti-PCSK9 antibody (hypercholesterolemia), Regeneron/sanofi-aventis
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Familial hypercholesterolemia [ICD-11: 5C80.00; ICD-10: E78.0] | Approved | [1], [2] | |
| Hypercholesterolaemia [ICD-11: 5C80.0] | Approved | [3] | ||
| Company |
Sanofi; Novo Nordisk
|
|||
| ADReCS Drug ID | BADD_D00072 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proprotein convertase subtilisin/kexin type 9 (PCSK9) | Target Info | . | [2], [4], [5] |
| WikiPathways | PCSK9-mediated LDLR degradation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6744). | |||
| REF 2 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012 Jul 7;380(9836):29-36. | |||
| REF 5 | The dyslipidaemia market. Nat Rev Drug Discov. 2014 Nov;13(11):807-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.